Searched for: author:"Windhorst, A.D."
(1 - 4 of 4)
document
Raaphorst, R.M. (author), Savolainen, H. (author), Cantore, M. (author), van de Steeg, E. (author), van Waarde, A. (author), Colabufo, N.A. (author), Elsinga, P.H. (author), Lammertsma, A.A. (author), Windhorst, A.D. (author), Luurtsema, G. (author)
Positron emission tomography (PET) imaging of P-glycoprotein (P-gp) in the blood-brain barrier can be important in neurological diseases where P-gp is affected, such as Alzheimer’s disease. Radiotracers used in the imaging studies are present at very small, nanomolar, concentration, whereas in vitro assays where these tracers are characterized,...
article 2017
document
Vlaming, M.L. (author), van Duijn, E. (author), Dillingh, M.R. (author), Brands, R. (author), Windhorst, A.D. (author), Hendrikse, N.H. (author), Bosgra, S. (author), Burggraaf, J. (author), de Koning, M.C. (author), Fidder, A. (author), Mocking, J.A. (author), Sandman, H. (author), de Ligt, R.A. (author), Fabriek, B.O. (author), Pasman, W.J. (author), Seinen, W. (author), Alves, T. (author), Carrondo, M. (author), Peixoto, C. (author), Peeters, P.A. (author), Vaes, W.H. (author)
Preclinical development of new biological entities (NBEs), such as human protein therapeutics, requires considerable expenditure of time and costs. Poor prediction of pharmacokinetics in humans further reduces net efficiency. In this study, we show for the first time that pharmacokinetic data of NBEs in humans can be successfully obtained early...
article 2015
document
Turner, M.A. (author), Mooij, M.G. (author), Vaes, W.H.J. (author), Windhorst, A.D. (author), Hendrikse, N.H. (author), Knibbe, C.A.J. (author), Körgvee, L.T. (author), Maruszak, W. (author), Grynkiewicz, G. (author), Garner, R.C. (author), Tibbocl, D. (author), Park, B.K. (author), de Wildt, S.N. (author)
Important information gaps remain on the efficacy and safety of drugs in children. Pediatric drug development encounters several ethical, practical, and scientifîc chaflenges One barrier to the evaluation of medicines for children is a lack of Innovative methodologies that have been adapted to the needs of chiIdren This article presents our...
article 2015
document
Mooij, M.G. (author), van Duijn, E. (author), Knibbe, C.A.J. (author), Windhorst, A.D. (author), Hendrikse, N.H. (author), Vaes, W.H.J. (author), Spaans, E. (author), Fabriek, B.O. (author), Sandman, H. (author), Grossouw, D. (author), Hanff, L.M. (author), Janssen, P.J.J.M. (author), Koch, B.C.P. (author), Tibboel, D. (author), de Wildt, S.N. (author)
Results: Ten infants (aged 0.1–83.1 months) were included; one was excluded as he vomited shortly after administration. In nine patients, [14C]AAP and metabolites in blood samples were detectable at expected concentrations: median (range) maximum concentration (Cmax) [14C]AAP 1.68 (0.75–4.76) ng/L, [14C]AAP-Glu 0.88 (0.34–1.55) ng/L, and [14C...
article 2014
Searched for: author:"Windhorst, A.D."
(1 - 4 of 4)